Table 2.
Effect of the NOS3 rs2070744 on tumor response, progression-free survival, and overall survival.
| Variable | N | Tumor response | Progression-free survival | Overall survival | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ORR, n (%) | OR (95% CI) | p | DCR, n (%) | OR (95% CI) | p | Mean months (95% CI) | HR (95% CI) | p | Mean months (95% CI) | HR (95% CI) | p | ||
| NOS3 rs2070744 | |||||||||||||
| TC + CC | 24 | 13 (54) | 1.63 (0.58–4.56) | 0.351 | 20 (83) | 0.94 (0.25–4.44) | 1.000 | 7.5 (4.8–10.2) | 1 (ref) | 0.069 | 16.1 (12.7–19.4) | 1 (ref) | 0.075 |
| TT | 76 | 32 (42) | 64 (84) | 10.6 (8.9–12.4) | 0.60 (0.34–1.05) | 22.3 (20.2–24.4) | 0.46 (0.19–1.11) | ||||||
CI confidence interval, DCR disease control rate (objective response plus stable disease), HR hazard ratio, NOS3 nitric oxide synthase 3, OR odds ratio, ORR objective response rate (complete and partial response).